Catalyst Pharmaceuticals Inc (CPRX)

Receivables turnover

		Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	US$ in thousands	398,204	214,203	140,833	119,073	102,306
Receivables	US$ in thousands	53,514	10,439	6,619	5,987	10,537
Receivables turnover		7.44	20.52	21.28	19.89	9.71

December 31, 2023 calculation

Receivables turnover = Revenue ÷ Receivables
= $398,204K ÷ $53,514K
= 7.44

The receivables turnover ratio for Catalyst Pharmaceuticals Inc has fluctuated over the past five years. The ratio indicates how efficiently the company is managing its receivables. A higher receivables turnover ratio signifies that the company is collecting its accounts receivable more frequently during the year.

In 2023, the receivables turnover ratio was 7.44, showing a decrease compared to the previous year. This decrease suggests that the company may be taking longer to collect its accounts receivable in 2023.

In 2022, the receivables turnover ratio saw a significant increase to 20.52, indicating that the company improved its efficiency in collecting receivables compared to 2021. This improvement could be attributed to better credit policies or more effective collections processes.

Similarly, the receivables turnover ratio was relatively high in 2021 and 2020 at 21.28 and 19.89, respectively, reflecting strong collections performance during those years.

In 2019, the ratio was lower at 9.71, indicating that the company took longer to collect its receivables compared to the following years.

Overall, Catalyst Pharmaceuticals Inc has demonstrated varying levels of efficiency in managing its accounts receivable over the past five years, with fluctuations in the receivables turnover ratio reflecting changes in the company's collections practices and effectiveness.